Evaluating the relationship between treatments taken for erectile dysfunction on anad hocbasis and the occurrence of acute cardiovascular (CV) events poses important methodological challenges. The reasons for these challenges and proposed methods for overcoming them were discussed at the 7th Conference of the European Society of Pharmacovigilance [Ankara, Turkey; September 1999].